iCONNECT with Baxter Canada

Improving the Safety of High Risk Insulin Infusions with Dr. Kevin Hansen

23 min · 5. kesä 2023
jakson Improving the Safety of High Risk Insulin Infusions with Dr. Kevin Hansen kansikuva

Kuvaus

IV Insulin has been defined as a top-rated high-alert medication by the Institute for Safe Medication Practices, and yet options to improve the safety of these infusions have been limited until recently.  Dr. Kevin Hansen will discuss his experience using Myxredlin, a ready-to-administer insulin infusion product that has changed how many organizations manage these high-risk infusions in the US.  He will also introduce some of the concepts for consideration when organizations are exploring the introduction of ready-to-administer products including patient safety, pharmaco-economics, drug stability, human resource management, and workflows. Link to discussed publication:  https://www.pppmag.com/article/2655 [https://www.pppmag.com/article/2655]

Kommentit

0

Ole ensimmäinen kommentoija

Rekisteröidy nyt ja liity iCONNECT with Baxter Canada-yhteisöön!

Aloita maksutta

14 vrk ilmainen kokeilu

Kokeilun jälkeen 7,99 € / kuukausi. · Peru milloin tahansa.

  • Podimon podcastit
  • 20 kuunteluaikaa / kuukausi
  • Lataa offline-käyttöön

Kaikki jaksot

31 jaksot

jakson Improving the Safety of High Risk Insulin Infusions with Dr. Kevin Hansen kansikuva

Improving the Safety of High Risk Insulin Infusions with Dr. Kevin Hansen

IV Insulin has been defined as a top-rated high-alert medication by the Institute for Safe Medication Practices, and yet options to improve the safety of these infusions have been limited until recently.  Dr. Kevin Hansen will discuss his experience using Myxredlin, a ready-to-administer insulin infusion product that has changed how many organizations manage these high-risk infusions in the US.  He will also introduce some of the concepts for consideration when organizations are exploring the introduction of ready-to-administer products including patient safety, pharmaco-economics, drug stability, human resource management, and workflows. Link to discussed publication:  https://www.pppmag.com/article/2655 [https://www.pppmag.com/article/2655]

5. kesä 202323 min